Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Ultimovacs has raised €28M across 1 funding round, most recently a Growth/Late round in Oct 2021. Based in Oslo, Norway; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-10-26 | Growth/Late | €28M |
| — |
| View deal → |
